Taliglucerase alfa
- Generic Name
- Taliglucerase alfa
- Brand Names
- Elelyso
- Drug Type
- Biotech
- CAS Number
- 37228-64-1
- Unique Ingredient Identifier
- N69L6LM4QU
- Background
Taliglucerase alfa is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase. It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.
- Indication
For the treatment of adult Type 1 Gaucher disease.
- Associated Conditions
- Gaucher Disease, Type 1, Gaucher Disease, Type III
Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial
- First Posted Date
- 2008-06-27
- Last Posted Date
- 2018-10-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 45
- Registration Number
- NCT00705939
- Locations
- 🇨🇱
Pontificia Universidad Catolica de Chile, Santiago, Chile
🇦🇺Bone Marrow Transplant Service, The Royal Melbourne Hospital, Parkville, Victoria, Australia
🇺🇸Department of Human Genetics, Emory University School of Medicine, Decatur, Georgia, United States
A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease
- Conditions
- Gaucher Disease
- Interventions
- First Posted Date
- 2006-09-14
- Last Posted Date
- 2018-10-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT00376168
- Locations
- 🇪🇸
Hospital Universitario Miguel Servet, Zaragoza, Spain
🇮🇱Shaare Zedek Medical Center, Jerusalem, Israel
🇮🇱Rambam Medical Center, Haifa, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.